CVM Quote, Financials, Valuation and Earnings

IGC Pharma, Inc. has a net margin of -- compared to CEL-SCI Corp.'s net margin of -953.4%. CEL-SCI Corp.'s return on equity of -266.61% beat IGC Pharma, Inc.'s return on equity of -94.42%.

CEL-SCI Corp. has a consensus price target of $42.50, signalling upside risk potential of 575.68%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1141.72%. Given that IGC Pharma, Inc. has higher upside potential than CEL-SCI Corp., analysts believe IGC Pharma, Inc. is more attractive than CEL-SCI Corp..

CEL-SCI Corp. has a beta of 0.487, which suggesting that the stock is 51.259% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

CEL-SCI Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI Corp. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

CEL-SCI Corp. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. CEL-SCI Corp.'s net income of -$5.7M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, CEL-SCI Corp.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI Corp. is -- versus 22.66x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to CEL-SCI Corp.'s net margin of -255.85%. CEL-SCI Corp.'s return on equity of -266.61% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

CEL-SCI Corp. has a consensus price target of $42.50, signalling upside risk potential of 575.68%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that CEL-SCI Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe CEL-SCI Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

CEL-SCI Corp. has a beta of 0.487, which suggesting that the stock is 51.259% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

CEL-SCI Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. CEL-SCI Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

CEL-SCI Corp. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. CEL-SCI Corp.'s net income of -$5.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, CEL-SCI Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI Corp. is -- versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -- compared to CEL-SCI Corp.'s net margin of 13.19%. CEL-SCI Corp.'s return on equity of -266.61% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

CEL-SCI Corp. has a consensus price target of $42.50, signalling upside risk potential of 575.68%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 539.54%. Given that CEL-SCI Corp. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Protalix Biotherapeutics, Inc..

CEL-SCI Corp. has a beta of 0.487, which suggesting that the stock is 51.259% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

CEL-SCI Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI Corp. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

CEL-SCI Corp. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. CEL-SCI Corp.'s net income of -$5.7M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, CEL-SCI Corp.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI Corp. is -- versus 2.19x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to CEL-SCI Corp.'s net margin of --. CEL-SCI Corp.'s return on equity of -266.61% beat Palatin Technologies's return on equity of --.

CEL-SCI Corp. has a consensus price target of $42.50, signalling upside risk potential of 575.68%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than CEL-SCI Corp., analysts believe Palatin Technologies is more attractive than CEL-SCI Corp..

CEL-SCI Corp. has a beta of 0.487, which suggesting that the stock is 51.259% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

CEL-SCI Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

CEL-SCI Corp. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. CEL-SCI Corp.'s net income of -$5.7M is higher than Palatin Technologies's net income of --. Notably, CEL-SCI Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI Corp. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.